Highly effective combination for initial therapy for young, fit CLL patients

BestPractice | Jun 2019 | EHA 2019 |

The rate of bone marrow minimal residual diseaseinduced byibrutinibin combination with fludarabine, cyclophosphamide, rituximabisthe highest ever reported for a regimen treating a population of CLL patients unrestricted by prognostic marker status.  The safety profile of the combination therapy was generally favorable, with typical toxicities of ibrutinib and fludarabine, cyclophosphamideand rituximabobserved, and no additional toxicities discernable with the combination.